Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM

Aurora Investment Counsel bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 34,744 shares of the medical device company's stock, valued at approximately $2,340,000. DexCom comprises 1.2% of Aurora Investment Counsel's investment portfolio, making the stock its 25th largest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Reflection Asset Management acquired a new stake in DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom in the first quarter valued at $25,000. MCF Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at $32,000. Wellington Grp LLC raised its position in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC bought a new position in shares of DexCom in the fourth quarter valued at about $36,000. Institutional investors own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Bank of America reduced their target price on shares of DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a report on Monday, May 18th. Raymond James Financial restated a "strong-buy" rating and set a $94.00 price objective on shares of DexCom in a research report on Friday, July 31st. Benchmark boosted their price objective on DexCom from $77.00 to $82.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a research report on Friday, July 31st. Finally, Canaccord Genuity Group set a $90.00 target price on DexCom and gave the stock a "buy" rating in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $88.71.

DexCom Stock Up 0.3%

DXCM stock opened at $89.88 on Thursday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $91.96. The business has a 50-day simple moving average of $76.85 and a 200 day simple moving average of $70.67. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market cap of $33.92 billion, a PE ratio of 35.53, a price-to-earnings-growth ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the company posted $0.48 earnings per share. The business's revenue for the quarter was up 13.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director owned 52,852 shares of the company's stock, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is owned by insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source